CTIS2023-505283-11-00进行中（未招募）1 期
A phase IV, prospective, multicenter, open-label, mother-milk study to evaluate ofatumumab concentration in the breast milk of lactating women with relapsing forms of multiple sclerosis receiving ofatumumab (Kesimpta®) - COMB157G2410
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •1. Written informed consent must be obtained before any study assessment is performed., 2. Participant is female with a relapsing form of MS and at least 18 years of age at the time of providing consent., 3. Participant must be postpartum at the time of enrollment, plan to be exclusively breastfeeding and willing to provide breast milk samples., 4. Participant has delivered term infant (at least 37 weeks gestation)., 5.Participant must plan to initiate or re-initiate or have initiated or re-initiated treatment with ofatumumab between 2 to 24 weeks postpartum. The decision to be treated with ofatumumab and to breastfeed is made in accordance with the treating physician and must be completely independent of the decision to participate in this study.
排除标准
- •1. Use of any investigational drugs within 5 half-lives of enrollment, or within 30 days or until the expected pharmacodynamic effect has returned to baseline, whichever is longer., 9. Active infections, including mastitis (participant may be included once the infection is resolved)., 11. Participant with active hepatitis B disease prior to the initiation or re-initiation of ofatumumab. (Participant with positive hepatitis B serology should consult a liver disease expert before the start of treatment and should be monitored and managed following local medical standards to prevent hepatitis B reactivation.), 12. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases., 13. Any contraindication as per local label., 14. Participant who has an infant with any abnormality that may interfere with breastfeeding or confound the study assessment in the opinion of the Investigator., 10. Prior or current history of primary or secondary immunodeficiency, or participant in an otherwise severely immunocompromised state., 2. Participant taking medications prohibited by the protocol (see Section 6.6.2) at screening., 3. Pregnant woman, confirmed by positive serum pregnancy test during screening., 4. Females of childbearing potential should use effective contraception as per local label., 5. Participant has history of chronic alcohol abuse or drug abuse in the last year., 6. Participant has any medical, obstetrical, psychiatric or other medical condition that, in the opinion of the Investigator, can jeopardize or would compromise the subject’s ability to participate in this study or confound the study assessment., 7. Participant has history of breast implants, breast augmentation, or breast reduction surgery., 8. Participant has received anti-CD20 agents during the second and third trimesters of pregnancy.
研究者
相似试验
招募中
4 期
A clinical trial to study the effect of Alpelisib plus fulvestrant in Indian Patients with advanced or metastatic breast cancer (ABC or MBC) with a PIK3CA mutatioCTRI/2022/04/042205ovartis Healthcare Pvt Ltd
招募中
4 期
A clinical trial to study the effect of Capmatinib in Indian patients with Metastatic NSCLC (MET exon 14 skipping mutation positive)CTRI/2022/05/042549ovartis Healthcare Pvt Ltd
已完成
4 期
A prospective Phase IV study at different centers without any competitor,Single dose clinical study to assess the safety and efficacy of glabellar lines DYSPORT® in adult subjects for treatment of glabellar lines moderate-to-severe the area on frontal bone above the nose and between the eyebrowsCTRI/2018/11/016357Cliniexperts Services Private Limited105
招募中
4 期
A clinical study to assess the long-term immune response after primary vaccination and immune response after re-vaccination with typhoid conjugate vaccineCTRI/2019/07/019996Cadila Healthcare Ltd
进行中（未招募）
4 期
A study to evaluate the safety and efficacy of Dienogest in patients suffering from endometriosisCTRI/2020/10/028556Jagsonpal Pharmaceuticals Limited